Reference is made to the stock exchange notices from Aqua Bio Technology ASA (“ABTEC”) published on 12 February 2026 regarding the successful placement of a private placement of 2,000,000 new shares in the company, at a subscription price of NOK 5.00 per share, corresponding to the par value of the shares of the company following a reverse share split to be implemented prior to formal completion of the private placement. The following shareholders have had their holdings diluted as a consequence of the private placement and thereby surpassed a notifiable threshold. The number of shares has been presented on the basis of the reverse share split (50:1) having been completed, as this is intended to be completed prior to the formal completion of the private placement. Following completion of the private placement, RH Industri AS and Roger Hofseth will hold 464,355 shares in ABTEC, corresponding to 8.9% of the shares and votes in the company.

This disclosure is made pursuant to section 4-2 of the Norwegian Securities Trading Act.

Contacts
Kristian Flaten
CEO & CFO
Aqua Bio Technology ASA

Phone: +47 9509 2322
Email: kf@aquabiotech.no

About Us
Aqua Bio Technology ASA (ABTEC) is a technology and distribution group in skincare and nonfood. The group has distribution towards B2C and B2B, and offers freight, customs, and logistics services. The group also develops sustainable biotechnology for use in skincare products. Aqua Bio Technology is listed on Euronext Expand Oslo.

This notice is published by Kristian Flaten on the listed date and time.

This information has been submitted pursuant to the Securities Trading Act § 5-12 and MAR Article 17. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-15 23:25 CET.

Attachments
Aqua Bio Technology ASA: Disclosure of large shareholdings

Läs mer på MFN